Triclabendazole for the treatment of human fascioliasis and the threat of treatment failures.
Luis A MarcosVicente MacoAngelica TerashimaPublished in: Expert review of anti-infective therapy (2020)
Most cases of human fascioliasis are successfully treated with TCBZ, but some continue excreting eggs in the stools despite 1-2 standard of care regimens of TCBZ. A precise regimen is unclear for those patients who fail the initial treatment with TCBZ. Further clinical trials are needed to address the possible TCBZ emerging resistance.